Beta-blockers, trimethoprim-sulfamethoxazole, and the risk of hyperkalemia requiring hospitalization in the elderly: A nested case-control study

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 9, 2010, Pages 1544-1551

  Weir, Matthew A ^a   Juurlink, David N ^b,c,d   Gomes, Tara ^b   Mamdani, Muhammad ^b,c,d,e   Hackam, Daniel G ^a   Jain, Arsh K ^a   Garg, Amit X ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIPROFLOXACIN; COTRIMOXAZOLE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITROFURANTOIN; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLOXACIN; POTASSIUM SPARING DIURETIC AGENT;

AGED; ANTIBIOTIC THERAPY; ARTICLE; CANADA; CASE CONTROL STUDY; FEMALE; HIGH RISK PATIENT; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPERKALEMIA; MAJOR CLINICAL STUDY; MALE; RISK; URINARY TRACT INFECTION;

ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HOSPITALIZATION; HUMANS; HYPERKALEMIA; LOGISTIC MODELS; MALE; ODDS RATIO; PATIENT ADMISSION; POLYPHARMACY; POTASSIUM; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 77957301713     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01970310     Document Type: Article

References (57)

1. Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, Cadoret C, Fish LS, Garber L, Kelleher M, Bates DW: Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 289: 1107-1116, 2003 (Pubitemid 37430324)
2. Acker CG, Johnson JP, Palevsky PM, Greenberg A: Hyperkalemia in hospitalized patients: Causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Arch Intern Med 158: 917-924, 1998
3. Browning JJ, Channer KS: Hyperkalaemic cardiac arrhythmia caused by potassium citrate mixture. BMJ (Clin Res Ed) 283: 1366, 1981
4. Ettinger PO, Regan TJ, Oldewurtel HA, Khan MI: Ventricular conduction delay and asystole during systemic hyperkalemia. Am J Cardiol 33: 876-886, 1974
5. Freeman SJ, Fale AD: Muscular paralysis and ventilatory failure caused by hyperkalaemia. Br J Anaesth 70: 226-227, 1993
6. Desai AS, Swedberg K, McMurray JJ, Granger CB, Yusuf S, Young JB, Dunlap ME, Solomon SD, Hainer JW, Olofsson B, Michelson EL, Pfeffer MA: Incidence and predictors of hyperkalemia in patients with heart failure: An analysis of the CHARM Program. J Am Coll Cardiol 50: 1959-1966, 2007
7. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717, 1999
8. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309-1321, 2003 (Pubitemid 36384098)
9. Reardon LC, Macpherson DS: Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med 158: 26-32, 1998
10. Rimmer JM, Horn JF, Gennari FJ: Hyperkalemia as a complication of drug therapy. Arch Intern Med 147: 867-869, 1987
11. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351: 543-551, 2004 (Pubitemid 39025171)
12. Palmer BF: Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 351: 585-592, 2004
13. Schepkens H, Vanholder R, Billiouw JM, Lameire N: Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: An analysis of 25 cases. Am J Med 110: 438-441, 2001 (Pubitemid 32452330)
14. Wrenger E, Muller R, Moesenthin M, Welte T, Frolich JC, Neumann KH: Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: Analysis of 44 cases. BMJ 327: 147-149, 2003
15. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547-1559, 2008 (Pubitemid 351522739)
16. Jackevicius CA, Cox JL, Carreon D, Tu JV, Rinfret S, So D, Johansen H, Kalavrouziotis D, Demers V, Humphries K, Pilote L: Long-term trends in use of and expenditures for cardiovascular medications in Canada. CMAJ 181: E19-E28, 2009
17. Ewart HS, Klip A: Hormonal regulation of the Na(+)-K(+)-ATPase: Mechanisms underlying rapid and sustained changes in pump activity. Am J Physiol 269: C295-C311, 1995
18. Rosa RM, Silva P, Young JB, Landsberg L, Brown RS, Rowe JW, Epstein FH: Adrenergic modulation of extrarenal potassium disposal. N Engl J Med 302: 431-434, 1980 (Pubitemid 10169247)
19. Traub YM, Rabinov M, Rosenfeld JB, Treuherz S: Elevation of serum potassium during beta blockade: Absence of relationship to the renin-aldosterone system. Clin Pharmacol Ther 28: 765-768, 1980 (Pubitemid 11213112)
20. Bruinsma N, Filius PM, De Smet PA, Degener J, Endtz P, van den Bogaard AE, Stobberingh EE: Antibiotic usage and resistance in different regions of the Dutch community. Microb Drug Resist 8: 209-214, 2002
21. Kallen AJ, Welch HG, Sirovich BE: Current antibiotic therapy for isolated urinary tract infections in women. Arch Intern Med 166: 635-639, 2006
22. Kleyman TR, Roberts C, Ling BN: A mechanism for pentamidine-induced hyperkalemia: Inhibition of distal nephron sodium transport. Ann Intern Med 122: 103-106, 1995
23. Perazella MA: Drug-induced hyperkalemia: Old culprits and new offenders. Am J Med 109: 307-314, 2000
24. Perazella MA: Trimethoprim-induced hyperkalaemia: Clinical data, mechanism, prevention and management. Drug Saf 22: 227-236, 2000
25. Schlanger LE, Kleyman TR, Ling BN: K(+)-sparing diuretic actions of trimethoprim: Inhibition of Na+ channels in A6 distal nephron cells. Kidney Int 45: 1070-1076, 1994
26. Velazquez H, Perazella MA, Wright FS, Ellison DH: Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med 119: 296-301, 1993
27. Choi MJ, Fernandez PC, Patnaik A, Coupaye-Gerard B, D'Andrea D, Szerlip H, Kleyman TR: Brief report: Trimethoprim-induced hyperkalemia in a patient with AIDS. N Engl J Med 328: 703-706, 1993 (Pubitemid 23073373)
28. von EE, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. J Clin Epidemiol 61: 344-349, 2008 (Pubitemid 351289042)
29. Statistics Canada Census Report 2006. Available at http://www12.statcan. ca/census-recensement/2006/dp-pd/prof/92-591/details/Page.cfm?Lang=E&Geo1= PR&Code1=35&Geo2=PR&Code2=01&Data=Count&SearchText= Ontario&SearchType=Begins&SearchPR=01&B1=All&GeoLevel= &GeoCode=35. Accessed July 24, 2009
30. Hux JE, Ivis F, Flintoft V, Bica A: Diabetes in Ontario: Determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 25: 512-516, 2002 (Pubitemid 41103345)
31. Jong P, Gong Y, Liu PP, Austin PC, Lee DS, Tu JV: Care and outcomes of patients newly hospitalized for heart failure in the community treated by cardiologists compared with other specialists. Circulation 108: 184-191, 2003 (Pubitemid 36871301)
32. Juurlink D, Preyra C, Croxford R, Chong A, Austin P, Tu J, and Laupacis A. Canadian Institute for Health Information Discharge Abstract Database: A Validation Study. 2006. Toronto, Institute for Clinical Evaluative Sciences. 3-15-0090
33. Levy AR, O'Brien BJ, Sellors C, Grootendorst P, Willison D: Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 10: 67-71, 2003 (Pubitemid 37028596)
34. Al-Omran M, Tu JV, Johnston KW, Mamdani MM, Kucey DS: Outcome of revascularization procedures for peripheral arterial occlusive disease in Ontario between 1991 and 1998: A population-based study. J Vasc Surg 38: 279-288, 2003
35. Foxman B: Epidemiology of urinary tract infections: Incidence, morbidity, and economic costs. Am J Med 113 (Suppl 1A): 5S-13S, 2002
36. Austin PC: Using the standardized difference to compare- the prevalence of a binary variable between two groups in observational research. Communications in Statistics-Simulation and Computation 38: 1228-1234, 2009
37. Mamdani M, Sykora K, Li P, Normand SL, Streiner DL, Austin PC, Rochon PA, Anderson GM: Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ 330: 960-962, 2005 (Pubitemid 40592320)
38. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40: 373-383, 1987 (Pubitemid 17055592)
39. Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA: New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol 57: 1288-1294, 2004 (Pubitemid 40023149)
40. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ: Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 154: 854-864, 2001 (Pubitemid 33000813)
41. Altman DG, Bland JM: Interaction revisited: The difference between two estimates. BMJ 326: 219, 2003
42. Gullestad L, Dolva LO, Soyland E, Kjekshus J: Difference between beta-1-selective and non-selective beta-blockade during continuous and intermittent exercise. Clin Physiol 8: 487-499, 1988
43. Gullestad L, Dolva LO, Nordby G, Skaaraas K, Larsen S, Kjekshus J: The importance of potassium and lactate for maximal exercise performance during beta blockade. Scand J Clin Lab Invest 49: 521-528, 1989 (Pubitemid 19238762)
44. Castellino P, Bia MJ, DeFronzo RA: Adrenergic modulation of potassium metabolism in uremia. Kidney Int 37: 793-798, 1990 (Pubitemid 20056853)
45. Katz A, Sahlin K, Juhlin-Dannfelt A: Effect of beta-adrenoceptor blockade on H+ and K+ flux in exercising humans. J Appl Physiol 59: 336-341, 1985
46. Nowicki M, Miszczak-Kuban J: Nonselective beta-adrenergic blockade augments fasting hyperkalemia in hemodialysis patients. Nephron 91: 222-227, 2002 (Pubitemid 34621687)
47. Williams ME, Gervino EV, Rosa RM, Landsberg L, Young JB, Silva P, Epstein FH: Catecholamine modulation of rapid potassium shifts during exercise. N Engl J Med 312: 823-827, 1985
48. Shemer J, Modan M, Ezra D, Cabili S: Incidence of hyperkalemia in hospitalized patients. Isr J Med Sci 19: 659-661, 1983
49. Arthur S, Greenberg A: Hyperkalemia associated with intravenous labetalol therapy for acute hypertension in renal transplant recipients. Clin Nephrol 33: 269-271, 1990 (Pubitemid 20205931)
50. McCauley J, Murray J, Jordan M, Scantlebury V, Vivas C, Shapiro R: Labetalol-induced hyperkalemia in renal transplant recipients. Am J Nephrol 22: 347-351, 2002
51. Arrizabalaga P, Montoliu J, Martinez VA, Andreu L, Lopez PJ, Revert L: Increase in serum potassium caused by beta-2 adrenergic blockade in terminal renal failure: Absence of mediation by insulin or aldosterone. Proc Eur Dial Transplant Assoc 20: 572-576, 1983
52. Aggarwal A, Wong J, Campbell DJ: Carvedilol reduces aldosterone release in systolic heart failure. Heart Lung Circ 15: 306-309, 2006 (Pubitemid 44426256)
53. Takaichi K, Takemoto F, Ubara Y, Mori Y: Analysis of factors causing hyperkalemia. Intern Med 46: 823-829, 2007
54. Iyer S, Jones DH: Community-acquired methicillin-resistant Staphylococcus aureus skin infection: A retrospective analysis of clinical presentation and treatment of a local outbreak. J Am Acad Dermatol 50: 854-858, 2004 (Pubitemid 38685764)
55. Kaka AS, Rueda AM, Shelburne SA, III, Hulten K, Hamill RJ, Musher DM: Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 58: 680-683, 2006 (Pubitemid 44288140)
56. Szumowski JD, Cohen DE, Kanaya F, Mayer KH: Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother 51: 423-428, 2007 (Pubitemid 46185256)
57. Shea AM, Curtis LH, Szczech LA, Schulman KA: Sensitivity of International Classification of Diseases codes for hyponatremia among commercially insured outpatients in the United States. BMC Nephrol 9: 5, 2008